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Introduction Radiotherapy (RT) and radical prostatectomy (RP) are both evidence-based treatments for nonmetastatic prostate cancer (Pca) that decreased Pca mortality compared with noncurative treatment in randomized clinical trials [1, 2] . Recently, results from Prostate Testing for Cancer and Treatment, the first randomized clinical trial comparing RT, RP, and active monitoring, were reported [3] . After 10 yr of follow-up, there was no statistically significant difference in cancer-specific survival after RP versus RT, but there were only four deaths from Pca after RT and five after RP. In a meta-analysis of previous observational studies, the adjusted risk for Pca death was twice as high after RT compared with RP [4] .
Men treated with RT generally have worse cancer characteristics than those treated with RP, and they are also generally older and have more comorbidities, which may affect the probability of receipt of secondary cancer treatment if disease recurrence occurs [5] . Despite adjustment for covariates to decrease confounding, there remains concern for residual confounding in these previous observational studies comparing RT with RP.
The aim of this study was to provide risk estimates to inform contemporary treatment decision for men with nonmetastatic prostate cancer. We used data in a national population-based prostate cancer registry combined with data from other health care registries and demographic databases that are almost complete. To obtain the most upto-date risk estimates, we used period analyses to overcome issues regarding incomplete data, misclassification of bone metastasis, and subpar treatment that were present in the early study period.
Patients and methods
The study cohort included men in the National Prostate Cancer Register (NPCR) of Sweden diagnosed between January 1, 1998 and December 31, 2012 with Pca in clinical local stage T1c-T3 or Tx, any Gleason grade group (GGG), serum levels of prostate-specific antigen (PSA) <l00 ng/ml, no verified lymph node metastases (N0 or Nx), and no verified bone metastases (M0 or Mx), and treated with primary RT or RP [6] .
NPCR captures 98% of all Pca cases in the Swedish Cancer Registry, to which registration is mandated by law [7] . The registration to NPCR has recently been described in detail [7, 8] . proportion of cores containing cancer were retrieved from histopathology reports for 14 609 men (74% capture rate).
As previously described, NPCR has been linked to other nationwide population-based health care registries and demographic databases in the Prostate Cancer data Base Sweden (PCBaSe) [7, 9] . The National Patient
Registry contains information on in-patient care including surgical procedures and discharge diagnoses, coded according to International
Classification of Diseases system (ICD-9 or ICD-10) since 1987. Using data on discharge diagnoses for the 10 yr preceding the Pca diagnosis, men were classified into four comorbidity categories according to the Charlson comorbidity index (CCI) [10] . For assessment of socioeconomic status, we used data on civil status and educational level, categorized as low (9 yr of school), middle (10-12 yr), and high (13 yr).
Statistical analyses
Inclusion started on January 1, 1998, and follow-up started on the date of surgery for RP and date of start of RT and ended at the date of emigration, date of death, or December 31, 2014, whichever event came first. Cox proportional hazard models with age as time scale were used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) [11, 12] .
Analyses was stratified by two different risk score assessments, National Comprehensive Cancer Network (NCCN) and Cancer of the Prostate Risk Assessment (CAPRA) [13, 14] . A Wald test for the interaction between risk category and treatment was performed [15] . CAPRA is a prognostic model with scores from 0 to 10, based on age, PSA, GGG, clinical stage, and percent of biopsy cores with cancer.
To diminish influence from earlier time periods when data quality was poor and to obtain the most representative estimates for the outcome of contemporary RT and RP, period analysis was performed [17] . Period analysis is based on the results from left truncation. We stage is affected by differential misclassification [19] . Potential sources of bias were handled as described by Sterne et al [20] .
Absolute 10-yr risk of Pca death after RT and RP was calculated assuming a direct relation between the relative risk and absolute 10-yr risk estimates. First, the 10-yr risk of Pca death in men who had received either RT or RP treatments was estimated. By use of this estimate, the proportion of RT, and the observed relative risk, an absolute 10-yr risk difference was calculated.
Potential changes in misclassification of bone metastases during the study period were investigated using logistic regression on risk of Pca death within 3 yr from diagnoses. To assess the potential differential misclassification of comorbidity between men who received RT and those who received RP, differences in the change in CCI during follow-up between cases treated with RT or RP compared with their respective matched Pca-free men were calculated in three separate time-to-event analyses [21] . The significance level was set to p < 0.05, and all tests were two sided. Missing data were handled by chained equations with five imputation data sets for each missing value [22, 23] . Statistical analysis was performed with R, version 3.0.2 [24] .
Results
The final study cohort included 15 054 men treated with RT and 26 449 men treated with RP ( Fig. 1 ). In 1998-1999, fine needle aspiration was used in more than one-third of the cases with no information on GGG and cancer extent. From 2000 onward, the completeness of data improved drastically ( Supplementary Fig. 1 ). Men treated with RT had higher T stage, GGG, PSA level, and proportion of biopsies with cancer than men who underwent RP (Table 1) . Men treated with RT were also older, had a lower educational level, and higher comorbidity than those who underwent RP. The results stratified on CAPRA score showed a similar steady decrease in the difference between RT and RP with increasingly aggressive cancer: CAPRA scores 0-4, HR 1.52 (95% CI: 1.16-2.01); CAPRA scores 2-6, HR 1.14 (95% CI: 0.93-1.40); CAPRA scores 4-8, HR 1.09 (95% CI: 0.89-1.33); and CAPRA scores 6-10, HR 0.97 (95% CI: 0.75-1.25) (Fig. 2) . Ten years after treatment, 1% of men with CAPRA scores 0-4 and 13% of men with CAPRA scores 6-10 had died from Pca. The absolute difference in Pca death at 10 yr between men who had received RT or RP was <1% for all CAPRA scores. The improvement in outcome by year of treatment was more pronounced in men treated with RT than in men treated with RP (Fig. 3) .
Men who were planned for RT according to data in NPCR but ultimately did not receive RT were almost three times more likely to die from Pca than those who were planned for but did not receive RP (Pca mortality rate 17 vs 6 per 1000 person-years; Fig. 1 ). During the study period, the RT doses increased substantially, and robotic-assisted RP became the most commonly used surgical technique (Supplementary Table 1 
Discussion
In this nationwide population-based cohort study, the difference in Pca mortality after RT and RP for potentially curable disease was much smaller than that in previous studies.
A small difference in favor of RP persisted in men with lowand intermediate-risk Pca, for high-risk Pca there was no difference. However, the absolute difference in the risk of Pca death within 10 yr was <1% across all CAPRA risk categories.
The risk of death from Pca after RT and RP has previously been compared in 15 observational studies (Supplementary  Table 3 ). In comparison with these studies, the present study showed smaller differences in outcomes after RT compared with RP, including one study based on an earlier version of PCBaSe [5] .
There are several reasons why the risk estimates in this study differ from those of the previous studies. The previous PCBaSe study used the registered treatment in NPCR, whereas we only included men for whom the receipt of RT and RP were verified. Our study was stratified on disease severity, which was done in only three of the other studies (Supplementary Table 3 ). RT doses may have been suboptimal in previous studies, as doses were unknown in nine of the previous studies (Supplementary Table 3 ). In contrast, we had data from an audit on exact RT doses for 97% of the men (Supplementary Table 1 ). Further strengths are the comprehensive, nationwide population-based data from NPCR and other health care registers [19, 25, 26] . Our study included more confounders and the data had higher granularity than any previous study. For example, we had separately collected data on the proportion of biopsy cores positive for cancer, and such data were available in only four of the previous studies; Gleason grading was applied with of surgery (n = 1), and date mismatch (n = 11). b Later than 2 yr from the date of diagnosis. 
five categories in the current study, whereas 14 of the 15 previous studies applied fewer grade categories [27] . Limitations of our study included incomplete data, misclassification of bone metastases, and subpar RT in the early calendar time. To address this issue, we used period analysis, an analytical approach that increases the influence of data from more recent calendar time. Period analysis is arguably the best analysis to inform current treatment decisions [17] . The method was not developed for comparative studies, but we argue that to provide accurate information on the results of contemporary treatments more weight must be put on data from more recent calendar time. Further limitations of our study were lack of data on PSA density and total cancer extent in biopsies in millimeters, both of which have been related to the outcome [28, 29] . a RT-median 6.4 yr (Q 1 = 3.9 yr, Q 3 = 9.7 yr) and RP-median 7.0 yr (Q 1 = 4.3 yr, Q 3 = 9.9 yr). Age was used as time scale. Start of follow-up was at treatment start, that is, date of surgery for prostatectomy and first dose of radiation. Adjustments were done for M stage, T stage, Gleason grade groups, PSA modeled using a linear spline with knots # in PSA = 3, PSA = 10, interaction between PSA and Gleason grade group, proportion biopsy cores with cancer, mode of detection, CCI, educational level, and civil status. A higher HR denotes a higher risk of Pca death for men treated with RT. CAPRA is a scoring system from 0 to 10 based on age, PSA, Gleason score, clinical stage, and percent of biopsy cores involved with cancer. A high CAPRA score is associated with a poor prognosis [14] . Left truncation of data on January 1, 2011. PSA = prostate-specific antigen; RP = radical prostatectomy; RT = radiotherapy. a An assumption was made that the absolute 10-yr risk of Pca death for RT and RP is directly corresponding to the relative risk estimates. Then by considering the proportion of RT and the absolute 10-yr risk of Pca death for RT and RP combined in each CAPRA score category, an absolute 10-yr risk difference was calculated combining this with the relative risks.
Observational studies are prone to bias, and potential sources to such bias were recently reviewed in detail by Sterne et al [20] . All domains of bias that these authors described were considered in this study. Despite these efforts, our study was still affected by differential misclassification. For example, the rate of change in CCI during follow-up was slower for men treated with RP than after RT. Speculatively, this could lead to a higher chance of additional treatment at cancer recurrence for men treated with RP. Thus, despite that our data set was more comprehensive than in previous studies, there was still residual confounding and only randomized clinical trials can eliminate confounding by indication for treatment.
Most men with low-or intermediate-risk cancer received RP, and the relative risk of Pca death was somewhat lower after RP than after RT in these men. However, since Pca mortality was very low in these risk categories, this relative difference translated into minute absolute differ- 
ences in the risk of Pca death. In contrast, most men with high-risk cancer received RT, and in this risk category there was a substantially higher absolute risk of Pca death with no difference between RT and RP.
Conclusions
In comparison with previous studies, the difference in Pca mortality after RT and RP was much smaller in this study than in previous studies and very small in absolute terms. Thus, the choice between these two treatments should be guided by the risk of side effects and patient preference rather than by the risk of Pca death. Strong selection mechanisms affect treatment selection in comparative observational studies, and without detailed information on disease severity, comorbidity, and treatment, results from such studies will be biased.
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